[Effect of 1-ethyl-4-(2-morpholinoethyl)-3, 3-diphenyl-2-pyrrolidinone hydrochloride hydrate (doxapram) on respiration and circulation].
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002245:Carbon Dioxide / Q000097:blood; D002302:Cardiac Output / Q000187:drug effects; D003042:Cocaine / Q000494:pharmacology; D002818:Cordotomy; D004285:Dogs; D004315:Doxapram / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004357:Drug Synergism; D005260:Female; D005263:Femoral Artery; D006145:Guanethidine / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D009025:Morpholines / Q000494:pharmacology; D009538:Nicotine / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D010100:Oxygen / Q000097:blood; D010643:Phenoxybenzamine / Q000494:pharmacology; D012039:Regional Blood Flow / Q000187:drug effects; D012110:Reserpine / Q000494:pharmacology; D012119:Respiration / Q000187:drug effects*; D014439:Tyramine / Q000494:pharmacology
D009025:Morpholines; D010643:Phenoxybenzamine; D002245:Carbon Dioxide; D009538:Nicotine; D012110:Reserpine; D004315:Doxapram; D003042:Cocaine; D010100:Oxygen; D009638:Norepinephrine; D014439:Tyramine; D006145:Guanethidine